- 1 **TITLE:** The emergence of SARS-CoV-2 lineages and associated antibody responses among 2 asymptomatic individuals in a large university community
- 3
- 4 **AUTHORS & AFFILIATIONS:** Marlena R. Merling ¹, Amanda Williams ^{1,2}, Najmus Mahfooz ¹,
- 5 Marisa Ruane-Foster ¹, Jacob Smith ², Jeff Jahnes ², Leona W. Ayers ³, Jose A. Bazan ⁴, Alison
- 6 Norris ^{4,5}, Abigail Norris Turner ⁴, Michael Oglesbee ², Seth A. Faith ², Mikkel B. Quam ^{5,} *, Richard
- 7 T. Robinson $1, *$
- 8
- 9¹ Department of Microbial Infection & Immunity, The Ohio State University, Columbus, OH, USA
- 10 ² Infectious Disease Institute, The Ohio State University, Columbus, OH, USA
- 11 ³ Department of Pathology, The Ohio State University, Columbus, OH, USA
- 12 ⁴ Division of Infectious Disease, Department of Internal Medicine, The Ohio State University,
- 13 Columbus, OH, USA
- ⁵ Department of Epidemiology, The Ohio State University, Columbus, OH, USA
- 15 * Co-corresponding authors

ABSTRACT

 SARS-CoV-2 (CoV2) infected, asymptomatic individuals are an important contributor to COVID transmission. CoV2-specific immunoglobulin (Ig)—as generated by the immune system following infection or vaccination—has helped limit CoV2 transmission from asymptomatic individuals to susceptible populations (e.g. elderly). Here, we describe the relationships between COVID incidence and CoV2 lineage, viral load, saliva Ig levels (CoV2-specific IgM, IgA and IgG) and inhibitory capacity in asymptomatic individuals between Jan 2021 and May 2022. These data were generated as part of a large university COVID monitoring program and demonstrate that COVID incidence among asymptomatic individuals occurred in waves which mirrored those in surrounding regions, with saliva CoV2 viral loads becoming progressively higher in our community until vaccine mandates were established. Among the unvaccinated, infection with each CoV2 lineage (pre-Omicron) resulted in saliva Spike-specific IgM, IgA and IgG responses, the latter increasing significantly post-infection and being more pronounced than N-specific IgG responses. Vaccination resulted in significantly higher Spike-specific IgG levels compared to unvaccinated infected individuals, and uninfected vaccinees' saliva was more capable of inhibiting Spike function. Vaccinees with breakthrough Delta infections had Spike-specific IgG levels comparable to those of uninfected vaccinees; however, their ability to inhibit Spike binding was diminished. These data demonstrate that COVID vaccines achieved hoped-for effects in our community, including the generation of mucosal antibodies that inhibit Spike and lower community viral loads, and suggest breakthrough Delta infections were not due to an absence of vaccine-elicited Ig, but instead limited Spike binding activity in the face of high community viral loads.

INTRODUCTION

 Coronaviruses are single-stranded RNA viruses that cause respiratory disease in a range of mammalian hosts. The Coronavirus Disease 2019 (COVID-19, or COVID) pandemic began in December 2019, after transmission of a novel coronavirus to an individual living in China. The sequence homology of this novel coronavirus to severe acute respiratory syndrome associated coronavirus (SARS-CoV) led to its being named SARS-CoV-2 (CoV2). CoV2 spreads via aerosol and respiratory droplets, causing either an asymptomatic infection or a flu-like illness that affects multiple organ systems and presents as fever, cough, dyspnea, malaise, delirium and death. International spread of CoV2 was rapid, and by February 2020 it had spread to nearly every country in the world (*1*). Now, 3 years after its emergence, CoV2 is estimated to have infected ~630 million individuals and killed >6.5 million individuals worldwide (*2*). The United States has reported more deaths than any other country (*2*).

 Viruses mutate to varying degrees depending on the nature of their genome and the proofreading activity (or lack thereof) of associated polymerases. CoV2 is no exception to this, and within a year of its emergence multiple lineage variants of concern (VOCs) appeared in numerous countries. B.1.1.7 (now called Alpha) and B.1.351 (now called Beta) were the first VOCs to be identified in September 2020 (Alpha, in United Kingdom) and October 2020 (Beta, in South Africa), and contained numerous missense mutations affecting the Spike protein (*3, 4*). The Spike protein is essential for CoV2 infection of target cells and contains a receptor-binding domain (RBD) which recognizes and binds the host receptor angiotensin-converting enzyme 2 (ACE2) (*5*). The Alpha and Beta lineage RBD mutations lead to tighter Spike:ACE2 structural interactions (*6*) and increased the transmissibility of CoV2 (*7, 8*). In January 2021, the P.1. (now called Gamma) lineage was reported in Brazil to contain even more missense mutations in more genes, including Spike (*9*). As with Alpha, the mutations inherent to the Gamma lineage increased its transmissibility (*9*). Two additional lineages emerged in March 2021 and November 2021,

 respectively, and in time would supplant all prior lineages in the speed with which they spread: the Delta lineage, which was first reported in India (*10*), and the Omicron lineage, reported in southern Africa (*11*). CoV2 continues to evolve, and deaths due to COVID continue to cause overall declines in life expectancy for many countries, including the United States (*12, 13*).

 After previous coronavirus disease outbreaks, such as those caused by SARS-CoV and Middle East respiratory syndrome coronavirus (MERS-CoV), animal models and other experimental systems demonstrated that coronavirus-specific antibodies are generated soon after infection (*14, 15*), and can block viral entry by interfering with the Spike:ACE2 interaction (*16-21*). In the upper respiratory tract and oral cavity, antibodies are generated by B cells in mucosa-associated lymphoid tissue (MALT) and regional draining lymph nodes, typically within several days of antigen encounter, and comprise several isotypes (IgM, IgA and IgG) which differ in their secretion kinetics and effector mechanism. IgM is often the first isotype to appear following antigen exposure, and eliminates viruses by precipitating the membrane attack complex on virus-infected cells (i.e. the classical complement pathway). In the context of CoV2 infection, however, IgA dominates the early neutralizing antibody response at mucosal sites (*22*). IgA, a weak inducer of the complement pathway, protects mucosal sites by blocking and sterically hindering antigen interaction with the epithelial surface, trapping it in mucus which is eventually cleared via peristalsis. IgG is often the last isotype to appear following antigen exposure but is the most versatile in terms of effector mechanisms and durability, as the B cells which produce IgG can become plasma cells that reside in bone marrow and continuously secrete IgG for months to years.

 The fact that coronavirus-specific Ig is secreted following natural infection, long-lived, and able to disrupt Spike:ACE2 interactions are the foundations on which multiple monitoring, therapeutic and vaccine strategies against CoV2 have been built. Prior to mass PCR testing, CoV2-reactive

 Ig in sera was the only biomarker for monitoring CoV2 prevalence at a population level (*23*). The discovery that plasma of COVID-convalescent individuals contains polyclonal Ig with CoV2- neutralizing activity (*24*) paved the way for multiple clinical trials testing the efficacy of convalescent plasma therapy against COVID (*25*). Whether convalescent plasma therapy was efficacious remains debated (*26*). What is not debated, however, is the efficacy of vaccines which were designed to elicit Ig against CoV2. In the US, the first COVID vaccines available comprised either a two-dose encapsulated mRNA formulation (BNT162b2 or mRNA-1273) or a single-dose adenovirus vector formulation (Ad26.COV2.S). The US Food & Drug Administration (FDA) granted emergency use authorizations (EUA) for BNT162b2 and mRNA-1273 on Dec 11 2020 and Dec 18 2020, respectively (*27, 28*); the FDA EUA for Ad26.COV2.S was granted on Feb 27 2021 (*29*). The advent of these and other COVID vaccines led to dramatic declines in COVID morbidity and mortality (*30*), and—relative to vaccinated individuals—unvaccinated individuals are more likely to need hospitalization or die following CoV2 infection (*31*).

 Since interrupting the Spike:ACE2 interaction was the goal of now-approved vaccines (*32, 33*), and remains a goal of potential COVID therapies (*34, 35*), the continual emergence of new CoV2 lineages with numerous and diverse Spike mutations threatens our ability to prevent and treat future CoV2 infections. It is therefore important to understand the relationships between CoV2 lineage emergence, CoV2-specific Ig levels—as elicited by either natural infection or vaccination—and their neutralization capacity. This is especially true of asymptomatic individuals 109 who are PCR positive (PCR^{POS}), as they are estimated to account for 50-65% of all transmission (*36, 37*). Here, we describe the relationships between COVID incidence, CoV2 lineage, viral load, CoV2-specific Ig responses (IgM, IgA & IgG) and inhibitory capacity in the saliva of asymptomatic 112 PCR^{POS} individuals, as the oral cavity and saliva—in addition to being readily accessible—are important sites of CoV2 infection and transmission (*38*) (especially newer Omicron variants (*39-* 114 43)). CoV2-specific Ig responses were similarly assessed in PCR^{NEG} individuals with a history of

- 115 CoV2 infection and/or COVID vaccination with pre-Omicron vaccines. These data were generated
- 116 as part of a large university COVID monitoring program which occurred between Aug 2020 \rightarrow Jun
- 117 2022.

METHODS

 Institutional approval statement. This work was reviewed and approved by The Ohio State University Biomedical Sciences Institutional Review Board (ID #2021H0080). This work was also reviewed and approved by the Ohio State Institutional Biosafety Committee (IBC) (ID #2020R00000046).

 Saliva specimen collection and handling. The Ohio State COVID monitoring program was active from Aug 2020 through June 2022. As part of this program, saliva specimens were collected on a weekly basis from students, staff and faculty who self-reported as being asymptomatic at the time of specimen collection. On and prior to the day of saliva collection at one of several mass testing sites (**FIG 1A**), individuals were instructed to define themselves *symptomatic* if they had at least one or more of the following : fever, chills, shortness of breath, difficulty breathing, fatigue, muscle aches, body aches, headache, new loss of taste, new loss of smell, sore throat, congestion, runny nose, nausea, vomiting, or diarrhea. To prevent contagion, symptomatic individuals were instructed not to come to the mass testing site and were instead referred to a healthcare provider for follow-up (e.g. the campus student health clinic). Individuals were defined as *asymptomatic* if they had none of the symptomatic conditions listed above. On the day of testing, individuals were instructed to refrain from food or drink for 30 minutes prior to collection, and to gently eject saliva into the collection tube, swallowing first and keeping saliva free from mucus, until the 1 mL mark on a sterile conical was reached (i.e. passive drool method). Specimens from asymptomatic individuals were collected at each of the six Ohio State campuses in Franklin county (OSU-Columbus), Licking county (OSU-Newark), Richland county (OSU- Mansfield), Allen county (OSU-Lima), Marion county (OSU-Marion) and Wayne county (OSU- Wooster). Specimens were then couriered to the CLIA-approved Applied Microbiology Services Lab (AMSL) of the Ohio State Infectious Disease Institute (IDI) and analyzed in accordance with

144 the SalivaDirect assay, a clinical diagnostic test that is Emergency Use Authorization (EUA) 145 approved by the US Food & Drug Administration (FDA) for SARS-COV-2 detection (*44*). While 146 performing the SalivaDirect real time polymerase chain reaction (PCR), saliva samples were 147 stored in a 4°C cold room until they were deemed either PCR negative (PCR^{NEG}) or PCR positive 148 (PCR^{POS}) for CoV2. Per the SalivaDirect method (45), any sample with a C_T value \leq 40 was 149 considered PCR^{POS} for CoV2. The positive or negative status of the sample was reported to the 150 individual and regional public health authorities (Columbus Public Health, Ohio Department of 151 Health, ODH,) per state and federal policies at the time. PCR^{POS} saliva samples and select 152 PCR^{NEG} saliva samples were then removed from the 4°C cold room, aliquoted into microcentrifuge 153 tubes, frozen (-20°C) and analyzed for viral genome sequencing and lineage identification, as 154 well as host antibody response characterization.

155

156 **Sequencing and Lineage Identification:** PCR^{POS} saliva samples with a $C_T \leq 33$ had their whole 157 CoV2 viral genome sequenced and lineage assigned per the methods described in our previous 158 work (46) (samples with a $C_T > 33$ had insufficient viral RNA for sequencing). CoV2 genome copy 159 numbers were calculated via linear regression analysis, by comparison to the C_T values of 160 SalivaDirect reference standards. CoV2 genome sequences were submitted to the Global 161 Initiative on Sharing Avian Influenza Data (GISAID) database in a manner consistent with ODH 162 expectations and policies at that time, in as close to real time as possible. The abbreviations we 163 use for each lineage in this study and associated figures are as follows: $Cov2^{Arc}$, the ancestral 164 lineage of CoV2 which emerged from Wuhan, China; $Cov2^{US}$, the B.1.2 lineage which was among 165 the first detected in our region of the United States (46-48); CoV2^{Alpha}, the B.1.1.7 lineage or Alpha 166 variant of concern (VOC) which was first reported by the UK in Dec 2020 (3); CoV2^{Beta}, the B.1.351 167 lineage or Beta VOC which was first reported in South Africa in Dec 2020 (4); CoV2^{Gamma}, the P.1 168 lineage or Gamma VOC which was first reported in Brazil in Jan 2021 (9); CoV2^{Delta}, the B.1.617.2

169 Iineage or Delta VOC which was first reported in India in Dec 2020 (10); CoV2^{Omicron}, the B.1.1.529 lineage or Omicron VOC which was first reported in South Africa in Nov 2021 (*11*); 171 CoV2^{O-BA.1}, the BA.1 variant of CoV2^{Omicron}; CoV2^{O-BA.2}, the BA.2 variant of CoV2^{Omicron}; CoV2^{O-BA.4}, 172 the BA.4 variant of CoV2^{Omicron}; CoV2^{O-BA.5}, the BA.2 variant of CoV2^{Omicron}. The nonsynonymous Spike mutations which distinguish these lineages are depicted in supplemental **FIG S1**. Any lineage which was not a VOC or otherwise not mentioned above (e.g. Epsilon) is labeled "Non-VOC."

 COVID wave designations and comparisons. We defined a COVID wave within our university 178 community as when new PCR^{POS} case counts rose above the overall period median for \geq 3 weeks in a row (the overall period being Jan 2021 through Jun 2022). For comparisons to COVID incidence in surrounding counties, we accessed publicly available ODH data via their public-facing dashboard (accessed Nov 14 2022).

 Measuring Binding Antibody Levels in Saliva: After PCR results were reported (typically within 184 24 hours of specimen collection), PCR^{POS} and select PCR^{NEG} specimens were removed from the 4°C cold room, aliquoted into microcentrifuge tubes containing Triton X-100 to inactivate CoV2 186 (final concentration: 1% Triton X-100) (49). PCR^{NEG} samples were selected based on the donors' having had either a prior CoV2 infection (allowing us to measure durability of the antibody response following natural infection) or their having been vaccinated against COVID (allowing us to compare the antibody responses of uninfected vaccinated individuals to those of infected vaccinated individuals, a.k.a. breakthrough infections). All samples were treated identically 191 regardless of whether they were PCR^{POS} or PCR^{NEG} . Following the addition of Triton X-100, samples were vortexed and allowed to incubate for 1 hour at room temperature (*49*). Samples were subsequently stored at -80°C until the antibody levels in all samples could be measured at the same time, thus eliminating batch effects. The Meso Scale Diagnostics (MSD) V-Plex platform

 was used to measure the concentration of CoV2 antigen specific immunoglobulin (IgM, IgA and/or 196 IgG) in PCR^{POS} and PCR^{NEG} samples. Briefly, the MSD V-Plex assay comprises a 96-well plate which, within each well, contains multiple spots that were coated with defined antigens. For our 198 study, these antigens included recombinant forms of three $CoV2^{Arc}$ lineage proteins 199 (Nucleocapsid [N], Spike, and the Spike Receptor Binding Domain [RBD]), as well as CoV2^{Alpha} 200 Spike, CoV2^{Beta} Spike, CoV2^{Gamma} Spike, and CoV2^{Delta} Spike (FIG S1). The Spike antigens consisted of the trimerized form of the ectodomain; the N antigen consisted of the full-length protein. Antibodies in the sample bind to the antigens, and reporter-conjugated secondary antibodies were used for detection. Saliva samples were thawed on ice and diluted by a factor of 10 in the diluent provided in the V-Plex assay kit for each assay. The V-Plex assays were performed according to manufacturer instructions, and plates were read on an MSD instrument which measures light emitted from reporter-conjugated secondary antibodies. Using MSD's analysis software, the light signal measured by the MSD instrument was converted into arbitrary units (AU) representing amount of antibody present relative to the standard curve of the assay. 209 The AU values for IqM , IqA and IqG binding to $CoV2^{Anc}N$, Spike, and Spike RBD were transformed to WHO binding antibody units (BAU) via validated WHO standards and conversion factors provided by MSD. The AU values for IgM, IgA and IgG binding to other forms of N or Spike (i.e., those of VOC) cannot be converted to WHO BAU, as there are no WHO standards for these 213 recombinant proteins. For this reason, the levels of each Ig isotype which bind to $Cov2^{Aipha}$, $COV2^{Beta}$, CoV2^{Gamma}, and CoV2^{Delta} forms of Spike are expressed as AU.

 Spike inhibition assay. The capacity of saliva specimens to inhibit Spike activity was quantified using a commercially available ACE2 displacement assay (MSD COVID-19 ACE2 Neutralization Kit method). Plate-bound Spike was incubated with diluted saliva (the same specimens used for Ig measurements) per manufacturer protocols, followed by washing and addition of a luminescent probe-conjugated, recombinant form of human ACE2. The extent to which luminescence declined

221 relative to non-saliva (i.e., diluent only) treated wells was used to derive a percent inhibition value 222 for each individual sample, using the following formula: $%$ inhibition = 1 – (saliva sample 223 luminescence value / diluent only luminescence value) \times 100.

 Graphing and statistics. Graphs were generated in RStudio or GraphPad. All statistical tests were performed in RStudio. Data was tested for normality using the Kolmogorov-Smirnov test and for equal variance using the Bartlett test of homogeneity of variances. For data that did not have normal distribution, the Kruskal-Wallis rank sum test was used to determine if there were significant differences between groups in unpaired datasets, and the Friedman rank sum test was used in paired datasets. Within those datasets, the significant differences between groups were identified via an unpaired or paired Wilcoxon rank sum test as appropriate with Benjamini- Hochberg p value adjustment method. For the neutralization data which contained several zero values, the Shapiro-Wilk normality test was used, followed by the Bartlett test of homogeneity of variances. The Kruskal-Wallis rank sum test was used to determine if significant differences were present, followed by Dunn's test with Benjamini-Hochberg p value adjustment method to identify which groups were significantly different. Differences between groups were considered significant if *P* < 0.05 and are graphically indicated by 1 or more asterisks (**P* < 0.05; ***P* < 0.005; ****P* < 0.0005).

240 **Abbreviations.** The following abbreviations are used throughout our manuscript: **PCR^{POS}**, an 241 individual or saliva specimen that was PCR positive for CoV2 (C_T value ≤ 40); PCR^{NEG}, an individual or saliva specimen that was PCR negative for CoV2; **Spike** and **N,** unless otherwise stated the Spike and N proteins of CoV2 (not any other coronavirus); **CoV2-Ig**, immunoglobulin 244 of any isotype that recognizes any CoV2 antigen; **IgM^{Spike}, IgM that recognizes Spike**; IgA^{Spike}, 245 IgA that recognizes Spike; **IgG^{Spike}, IgG that recognizes Spike; IgG^{RBD}, Ig**G that recognizes the

- 246 Spike Receptor Binding Domain; **IgG^N**, IgG that recognizes the N protein; Vax^{POS}, an individual
- 247 who was fully vaccinated against COVID (but not boosted) prior to saliva specimen collection;
- 248 Vax^{NEG}, an individual who was not fully vaccinated against COVID prior to saliva specimen
- 249 collection; **New^{POS}**, an individual who at the time of saliva collection was PCR^{POS} for the first time;
- 250 **Prior^{POS}**, an individual who at the time of saliva collection was PCR^{NEG} but who had a prior CoV2
- 251 infection (i.e. the individual had been PCR^{POS} 3-9 months prior).

RESULTS

I. Study overview

 The first confirmed cases of COVID in the state of Ohio were reported on Mar 9 2020 (*50*). The Ohio State University suspended on campus activities the same day (*51*) and subsequently developed a campus wide plan to monitor the incidence of CoV2 infection among its students, staff and faculty (*52*). Individuals participating in this monitoring program, which formally began in Aug 2020, provided saliva on a weekly basis for COVID testing. Prior to testing, individuals who self-reported as being symptomatic were not tested and were instead given a clinical referral (see *Methods* for additional details). Individuals who self-reported as being asymptomatic provided a saliva specimen via a passive drool method at each of our six university campuses (**FIG 1A**). Specimens were assessed by our CLIA-certified lab for the presence of CoV2 using real-time quantitative reverse transcription PCR (qRT-PCR). Specimens were not pooled prior to testing. qRT-PCR results were reported to the individual and the regional public health authority per state 267 and federal policies at the time. If a specimen had a C_T value \leq 40 it was considered positive for 268 CoV2 virus (PCR^{POS}). Per our Institutional Review Board (IRB) approved protocols and workflows 269 (FIG 1B), PCR^{POS} saliva samples were subsequently used for CoV2 lineage identification and CoV2-specific immunoglobulin (CoV2-Ig) measurements. In some instances, select saliva 271 samples that were negative for CoV2 virus (PCR^{NEG}) were also collected, the reasons for which 272 will be made clear in sections below. The relationships between these molecular and immunological readouts to one another, as well as to coded data concerning the prior infection status and vaccination status of the saliva donor, are described below for the period spanning Jan 2021 (before COVID vaccines were widely available to students in our university community) to June 2022, when the monitoring program ended. See Methods for details regarding saliva collection, symptomatic versus asymptomatic designation, qRT-PCR, CoV2 lineage identification,

 CoV2-Ig measurements, and statistical analyses. In total, >850,000 diagnostic PCR tests were performed by our lab during this monitoring program.

II. The incidence of CoV2 positivity in our university community occurred in waves which reflected those occurring in surrounding regions.

284 The incidence of new PCR^{POS} cases among asymptomatic individuals in our university 285 community, for the period spanning Jan 2021 \rightarrow June 2022, is shown in **FIG 2**. COVID monitoring occurred before Jan 2021; however, because the bulk of PCR testing at that time was contracted to a commercial entity, our access to the raw PCR data before Jan 2021 is limited. Above these data are two timelines relevant to data interpretation, indicating when Ohio COVID vaccination 289 policies shifted from prioritizing at risk populations (e.g. elderly) to anyone \geq 16 years of ages well as the deadlines for all our community members (i.e. university students, faculty and staff) to have received their first and second COVID doses (Oct 15 2021 and Nov 15 2021, respectively) (*53*). Indicated below the data are corresponding intervals in the academic calendar, which will be 293 referred to in subsequent sections. We identified 11,989 PCR^{POS} individuals between Jan 294 2021 \rightarrow June 2022; the median, mean and maximum new PCR^{POS} cases per test day were 15, 34 and 523, respectively. There were, however, six time periods when the new case counts rose 296 above the overall period median for \geq 3 weeks in a row. These six time periods are hereafter 297 referred to as Waves 1–6 and spanned the following dates: *Wave 1*, Jan 11 2021 \rightarrow Jan 29 2021; *Wave 2, Feb 22 2021→ Mar 12 2021; Wave 3, Mar 22 2021→ Apr 16 2021; Wave 4, Aug 16* 299 2021→ Sep 24 2021; *Wave 5*, Nov 15 2021→ Feb 18 2022; *Wave 6*, Apr 18 2022→ May 6 2022. The waves of COVID incidence amongst asymptomatic individuals in our university community mirrored (rather than preceded) the waves of COVID incidence in the counties surrounding each university campus (*54*) (supplemental **FIG S2**).

303

304 **III. Prior to community vaccine requirements being established, CoV2 was becoming** 305 **progressively more concentrated in the saliva of asymptomatic individuals.**

306

 The emergence of CoV2 lineage variants in multiple Ohio communities (*55-61*) with potential for greater infectivity and/or transmissibility led us to assess the relationship between CoV2 309 abundance in saliva and variant identity. We used the qRT-PCR cycle threshold (C_T) value as a 310 readout of CoV2 abundance, as the SalivaDirect C_T value is inversely proportional to CoV2 viral 311 load (i.e. a lower C_T value corresponds to higher CoV2 RNA levels in the tested sample) (45), and 312 a commonly used as a proxy for probability of transmission (i.e. a lower C_T value correspond to higher transmission probability) (*62-66*). Variant identity was determined by next generation sequencing of the entire CoV2 genome and subsequent alignment with Global Initiative on Sharing Avian Influenza Data (GISAID) reference sequences. During the entire monitoring period, CoV2 genome sequences were submitted to the GISAID database in a manner consistent with ODH expectations and policies at that time, in as close to real time as possible.

318

319 The weekly composite and daily individual C_T values of each PCR^{POS} individual over this period 320 are shown in **FIG 3A** and **FIG 3B**, respectively, with color annotations in **FIG 3B** indicating the 321 lineage identity. The same data are presented in two ways (weekly composite versus daily 322 individual) in order to best illustrate the following trends: During Wave 1 (Week 2 of Jan 2021 \rightarrow 323 Week 4 of Jan 2021), the median weekly C_T values of all PCR^{POS} saliva samples ranged between 324 29 - 30.5 (**FIG 3A**). During Wave 2 (Week 4 of Feb 2021 \rightarrow Week 2 of Mar 2021) the median 325 weekly C_T values ranged between 28 - 30.5 (FIG 3A). The median C_T range lowered and tightened 326 during Wave 3 (Week 4 of Mar 2021 \rightarrow Week 2 of Apr 2021) median weekly C_T values ranged 327 from 28.5 - 29.5 (**FIG 3A**). The number of tests performed fell precipitously during Jun 2021 and

328 Jul 2021, as the campus population is minimal during the summer months; therefore, we are 329 reluctant to draw conclusions from or otherwise compare Summer 2021 C_T value data to the prior 330 semester, when testing volume was higher. Upon resumption of high-volume testing during the 331 later weeks of August 2021, which marked the beginning of the Autumn 2021 semester and Wave 332 4 (Week 3 of Aug 2021 \rightarrow Week 3 of Sept 2021), we noted the lowest median C_T range of all 333 waves (27.0 - 27.5) (**FIG 3A**). The cumulative C_T data during each wave (**FIG 3C**) and 334 extrapolated CoV2 genome copy concentrations (**FIG 3D**) are consistent with Wave 4 saliva 335 samples having the highest virus concentrations of all waves. Wave 5 was the longest wave 336 (Week 3 of Nov 2021 \rightarrow Week 2 of Feb 2022) with daily PCR^{POS} cases reaching a maximum 337 of 523 on Jan 11, 2022. The C_T value range during Wave 5, which followed our community 338 deadline for vaccine requirements, was significantly higher than that of Wave 4 (**FIG 3B**). The last 339 wave before the COVID monitoring program ended, Wave 6 (Week 2 of Apr 2022 \rightarrow Week 1 of 340 May 2022), had lower C_T values than Wave 5 (**FIG 3B**). The lowest C_T value we ever observed 341 was on Feb 18 2021 (C_T =14.2).

342

343 **IV. Each wave of CoV2 positivity corresponded to the emergence of a new CoV2 lineage** 344 **within our community.**

345

346 The CoV2 lineages present in each individual PCR^{POS} sample during the same time periods as 347 above are shown in **FIG 3B**, exceptions being samples with a C_T value of >33 as these could not 348 be sequenced due to the viral RNA levels being too low. Among sequenced samples, the median 349 and mean ages of infected individuals were 21 and 23, respectively, and varied minimally during 350 the monitoring period (supplemental **FIG S3**). Males were more likely to meet sequencing criteria 351 (i.e. a $C_T \le 33$) than females during Waves 1-3 (supplemental FIG S4); this was not true of later 352 Waves, however, and female representation was higher during the entire monitoring period

353 overall (supplemental **FIG S4**). During the period spanning Jan 2021 to mid-Feb 2021, the 354 predominant lineage was B.1.2, which we hereafter refer to as $CoV2^{US}$ since it was among the 355 first detected in our region of the United States $(46-48)$. The period of CoV2^{US} lineage 356 predominance corresponds to Wave 1 in our community (**FIG 2, FIG 3B**). Beginning mid-Feb 357 2021 and extending to mid-Mar 2021 was a period of time when an array of lineages which we 358 collectively refer to as "non-VOC" were predominant, as they were more diverse compared to 359 earlier and later testing periods and were never considered to be Variants of Concern (VOC). 360 Although the CoV2^{US} lineage was still being detected. Wave 2 primarily comprised of non-VOCs 361 (**FIG 3B**). As the Ides of March approached in 2021, so too did two VOCs begin appearing with 362 increasing frequency: the Alpha VOC (CoV2^{Alpha}) and Gamma VOCs (CoV2^{Gamma}). CoV2^{Alpha} and 363 CoV2^{Gamma} were widely considered at that time to be more transmissible than previous lineages 364 (9, 67). CoV2^{Alpha} and CoV2^{Gamma} were the primary lineages detected during Wave 3 (**FIG 3B**), 365 and continued to predominate among the few positive samples collected during May 2021. The 366 Beta VOC (CoV2^{Beta}) only appeared once in our university community (Apr 15, 2021). Beginning 367 Jun 2021 and continuing through Dec 2021 the new Delta VOC (CoV2^{Delta}) made up the vast 368 majority of PCR^{POS} saliva samples (FIG 3B). CoV2^{Delta} is more transmissible than CoV2^{Alpha} and 369 CoV2^{Gamma} (68), and the period in which CoV2^{Delta} predominated coincided with COVID Wave 4 370 in our community (**FIG 2**). Wave 5, the penultimate and largest COVID wave, coincided with the 371 emergence and dominance of the Omicron VOC (CoV2^{Omicron}) subvariant, BA.1 (CoV2^{O-BA.1}). 372 Wave 6, final wave before our COVID monitoring program ended, was dominated by the 373 CoV2^{Omicron} subvariant BA.2 (CoV2^{O-BA.2}) (FIG 3B). When considered alongside the C_T values and 374 CoV2 genome copy numbers that characterized each wave (**FIG 3C-D**), the above data 375 demonstrate that the shift from $CoV2^{US} \rightarrow CoV2^{Alpha}/CoV2^{Gamma} \rightarrow CoV2^{Delta}$ coincided with the 376 virus becoming progressively more concentrated in the saliva of asymptomatic individuals, this 377 trend ending after community vaccine requirements were established.

V. Among pre-Omicron lineages, CoV2Delta 379 **elicited the highest levels of Spike-specific IgA** 380 **and IgG in unvaccinated, asymptomatic individuals**

381

382 In symptomatic CoV2 PCR^{POS} individuals, CoV2-specific Ig levels in the circulation and airways 383 increase at variable rates depending on the isotype (*22*). To assess whether CoV2-specific Ig was 384 detectable in the saliva of asymptomatic CoV2 PCR^{POS} individuals, as well as whether levels of 385 the same Ig varied depending on the CoV2 lineage present, we used the same samples described 386 above (i.e. those used for lineage identification) to measure saliva levels of CoV2 Spike-specific 387 IgM (IgM^{Spike}), CoV2 Spike-specific IgA (IgA^{Spike}) and CoV2 Spike-specific IgG (IgG^{Spike}) (**FIG 4**). 388 Individuals vaccinated against COVID were excluded from this analysis (the vaccination record 389 of each person in our university community was closely monitored during this time period), and 390 saliva samples from individuals infected with $CoV2^{Anc}$, $CoV2^{Aipha}$ and $CoV2^{Gamma}$ were collected 391 prior to COVID vaccines being widely available in our community; therefore, no vaccine-elicited 392 antibody responses would be expected in these samples. Among individuals infected with 393 CoV2^{Delta}, only unvaccinated individuals were included in the FIG 4 analysis. To eliminate viral 394 load as a confounding variable, only PCR^{POS} saliva samples with similar C_T range were used for 395 Ig comparisons (C_T range = 22-26). PCR^{NEG} saliva collected in early 2020 from healthy individuals 396 Iiving in the US and no COVID history were used to estimate "pre-pandemic" levels of IgM^{Spike}, 397 IgA^{Spike} of IgG^{Spike} binding.

398

Saliva IgMSpike (**FIG 4A**), IgASpike (**FIG 4B**) and IgGSpike 399 (**FIG 4C**) data are shown relative to which 400 CoV2 lineage was detected in the same saliva donor (CoV2^{US}, CoV2^{Alpha}, CoV2^{Gamma} or CoV2^{Delta}) 401 and are expressed as WHO binding antibody units, or BAUs. As shown in **FIG 4A-C**, respectively, 402 nearly all PCR^{POS} individuals had saliva IgM^{Spike}, IgA^{Spike} and IgG^{Spike} levels that were above "pre-403 pandemic" levels, regardless of whether they were infected with CoV2^{US}, CoV2^{Alpha}, CoV2^{Gamma} 404 or CoV2^{Delta}. There were, however, three noteworthy differences between PCR^{POS} individuals

405 depending on the lineage present. First, whereas individuals infected with CoV2^{US} and CoV2^{Alpha} 406 had similar IgM^{Spike} levels, those infected with CoV2^{Gamma} and CoV2^{Delta} had higher IgM^{Spike} levels 407 relative to those infected with CoV2^{US} (FIG 4A). Second, saliva IgA^{Spike} levels were similar 408 between individuals infected with $CoV2^{US}$, $CoV2^{Alpha}$ and $CoV2^{Gamma}$; $CoV2^{Delta}$ infected 409 individuals, on the other hand, had significantly higher IgA^{Spike} levels compared to those infected 410 with CoV2^{US}, CoV2^{Alpha} or CoV2^{Gamma} (FIG 4B). Third, saliva IgG^{Spike} levels were elevated in 411 CoV2^{Alpha}-infected individuals relative to CoV2^{US}-infected individuals (FIG 4C); however and 412 analogous to IgA^{Spike} differences (**FIG 4B**), CoV2^{Delta}-infected individuals had significantly higher 413 IgG^{Spike} levels compared to those infected with CoV2^{US}, CoV2^{Alpha} or CoV2^{Gamma} (FIG 4C). For 414 IgM^{Spike}, IgA^{Spike} and IgG^{Spike} measurements, the recombinant Spike antigen used for Ig detection 415 was identical to that of CoV2^{Anc}, as this enabled data transformation to WHO BAU (see *Methods*); 416 the same patterns were observed, however, when the same saliva samples were tested against 417 recombinant CoV2^{Alpha}, CoV2^{Beta}, and CoV2^{Gamma} Spike antigens (**Supplemental FIG S5).**

418

VI. Following infection of unvaccinated individuals, IgGSpike and IgGRBD 419 **persisted at higher levels in saliva than IgG^N** 420

421

422 To determine the extent to which CoV2-specific IgG in saliva was sustained over time, we 423 performed the analysis shown in **FIG 5** wherein saliva IgG^{Spike} levels, as well as Nucleocapsid 424 (N)-specific IgG (IgG^N) levels, were compared across two groups of individuals: "New^{POS}" 425 individuals who, at the time of saliva collection, were positive for either CoV2^{US} or CoV2^{Alpha}; 426 "Prior^{POS}" individuals who were uninfected at the time of saliva collection, but had been PCR^{POS} 427 $\,$ 3-9 months earlier. In this instance, saliva samples from Prior^{POS} individuals were collected in May 428 2021. Most individuals in our Prior^{POS} cohort were infected during the Autumn 2020 semester, 429 before COVID vaccines were available; therefore, any saliva $\log S_{pi}$ bresent would have

430 formed after natural infection (not vaccination). As in the previous figure, individuals with a record 431 of COVID vaccination were excluded from this analysis.

432

433 Among New^{POS} individuals, saliva $\lg G^N$ levels were similar regardless of whether they were 434 infected with CoV2^{US} or CoV2^{Alpha} (FIG 5A), as were saliva IgG^{Spike} levels (FIG 5B; note the data points in the first two columns of **FIG 5B** are the same as those in the first two columns of **FIG 4C**). Relative to New^{POS} individuals, saliva IgG^N levels in Prior^{POS} individuals were higher (FIG **5A**); however, the difference in saliva IgG^{Spike} levels between New^{POS} versus Prior^{POS} individuals 438 was more pronounced (FIG 5B). Saliva IgG^{Spike} levels were highest in Prior^{POS} individuals (FIG **5B**) and reacted against the Spike RBD domain (**FIG 5C**). These results indicate that although IgG^N and IgG^{Spike} both persist in saliva following natural infection, IgG^{Spike} persists at higher levels and reacts against Spike regions that are essential for ACE2 binding (i.e., the RBD).

442

VII. Individuals with breakthrough CoVDelta infections had comparable saliva IgGSpike 443 **levels** 444 **to those of uninfected, vaccinated individuals.**

445

446 During the period of Dec 2020 – Mar 2021, COVID vaccination was prioritized and available to 447 the elderly and other individuals at increased risk of severe disease (e.g. healthcare workers, first 448 responders). In Ohio, beginning on Mar 22 2021, individuals who were 16 years or older could 449 receive a COVID vaccine, including all college students (*69*). Despite the widespread availability 450 of vaccines by our Autumn 2021 semester, $Cov2^{Delta}$ lineage infections occurred among 451 unvaccinated (Vax^{NEG}) individuals and vaccinated (Vax^{POS}) individuals. The term "breakthrough 452 infection" is older than COVID (70) but is now commonly applied to individuals who are PCR^{POS} 453 despite their being Vax^{POS}. Since BNT162b2, mRNA-1273 and Ad26.COV2.S were each 454 designed to elicit an Ig response against CoV2 Spike (since it is essential for CoV2 infection of 455 ACE2-expressing cells), we assessed whether breakthrough infections with $CoV2^{Delta}$ were

456 associated with lower levels of Spike-specific Ig in saliva compared to PCR (neg) vaccinates. 457 Shown in **FIG 6** are saliva levels of IgM^{Spike} , IgA^{Spike} and IgG^{Spike} in three groups of individuals: 458 VAX^{NEG}PCR^{POS} individuals infected with CoV2^{Delta}, VAX^{POS}PCR^{POS} individuals infected with 459 CoV2^{Delta}, and VAX^{POS}PCR^{NEG} individuals. Saliva from VAX^{NEG}PCR^{POS} and VAX^{POS}PCR^{POS} 460 individuals was collected during Wave 4 (**FIG 2**), when community viral burdens were their highest 461 (**FIG 3D**); saliva from VAX^{POS}PCR^{NEG} individuals was collected shortly after Wave 4 had passed. 462 These results demonstrate that VAX^{POS}PCR^{POS} and VAX^{POS}PCR^{NEG} groups each had significantly 463 higher saliva IgG^{Spike} levels than VAX^{NEG}PCR^{POS} individuals (FIG 6C). Furthermore, the saliva 464 IgG^{Spike} levels of VAX^{POS}PCR^{POS} and VAX^{POS}PCR^{NEG} groups did not significantly differ from one 465 another (**FIG 6C**). Notably, although saliva IgM^{Spike} levels were indistinguishable across groups 466 (FIG 6A), VAX^{NEG}PCR^{POS} individuals were distinguished by the highest levels of saliva IgA^{Spike} 467 (FIG 6B). Similar trends were observed using recombinant CoV2^{Alpha}, CoV2^{Beta}, CoV2^{Gamma} and 468 CoV2^{Delta} Spike as capture antigens (**Supplemental FIG S6**). We conclude from this that COVID 469 vaccination increased saliva IgG^{Spike} levels in our university community as intended, the saliva 1470 lgG^{Spike} levels in all vaccinees being comparable (regardless of whether they had a breakthrough 471 CoV^{Delta} infection) and significantly higher than the saliva IgG^{Spike} levels of unvaccinated, infected 472 individuals.

473

VIII. Despite comparable Spike-specific Ig levels, CoV2Delta 474 **-infected vaccinee saliva was** 475 **less capable of Spike:ACE2 inhibition, relative to uninfected vaccinees.**

476

 Since the presence of CoV2-specific Ig does not equate to its having neutralization capacity (*71*), 478 we next compared the ability of Vax^{NEG}PCR^{POS}, Vax^{POS}PCR^{POS} and Vax^{POS}PCR^{NEG} saliva samples to inhibit Spike:ACE2 interactions. We quantified inhibitory activity using an ACE2 displacement assay (**FIG 7A**), wherein plate-bound Spike was incubated with the same saliva samples above (i.e., those of **FIG 6**), followed by washing and addition of a luminescent probe-

482 conjugated, recombinant form of human ACE2. The extent to which luminescence declined 483 relative to non-saliva treated wells was used to derive a percent inhibition value for each individual 484 sample (see *Methods* for additional details). The results of this analysis are shown in **FIG 7B** and 485 demonstrate that there were differences between cohorts, the inhibitory activity of VAX^{POS}PCR^{NEG} 486 saliva being significantly higher than that of Vax^{NEG}PCR^{POS} saliva (FIG 7B). The inhibitory activity 487 of Vax^{POS}PCR^{POS} saliva (median=12) was 50% higher than that of Vax^{NEG}PCR^{POS} saliva 488 (median=8), but 25% lower than that of Vax^{POS}PCR^{NEG} saliva (median=16); as a whole, however, 489 the inhibitory activity of Vax^{POS}PCR^{POS} saliva did not significantly differ from that of Vax^{NEG}PCR^{POS} 490 saliva, nor did it significantly differ from Vax^{POS}PCR^{NEG} saliva (FIG 7B). Within the Vax^{NEG}PCR^{POS} 491 cohort, there were no significant correlations between these samples' inhibitory activity and their 192 IgM^{Spike} (**FIG 7C**), IgA^{Spike} (**FIG 7D**) or IgG^{Spike} concentrations (**FIG 7E**). This was also true of the 493 Vax^{POS}PCR^{POS} cohort, as no significant correlations were observed between these samples' 494 inhibitory activity and their IgM^{Spike} (**FIG 7F**), IgA^{Spike} (**FIG 7G**) or IgG^{Spike} concentrations (**FIG 7H**). 495 Within the Vax^{POS}PCR^{NEG} cohort, there were significant correlations between samples' inhibitory activity and their IgASpike concentration (**FIG 7J**), as well as their IgGSpike 496 concentration (**FIG 7K**), but not their IgMSpike 497 concentration (**FIG 7I**). When considered alongside the data shown in **FIG 498 6, we conclude COVID vaccination led to increases in saliva IgG^{Spike} concentrations, the levels** 499 being similar between vaccinees who had a breakthrough CoV2^{Delta} infection (Vax^{POS}PCR^{POS}) and 500 vaccinees who did not (Vax^{POS}PCR^{NEG}), but that during Wave 4 the antibodies in Vax^{POS}PCR^{POS} 501 saliva were limited in their ability to inhibit Spike, the inhibition values being intermediate between 502 Vax^{POS}PCR^{NEG} saliva (which had the highest inhibition values) and Vax^{NEG}PCR^{POS} controls (which 503 had the lowest inhibition values).

DISCUSSION

 The spread of CoV2 to the US marked the beginning of an extraordinary period wherein a novel respiratory virus transmitted and evolved in a population with no prior immunity, our primary defenses being behavioral changes (e.g., masking and physical distancing) until the advent of effective vaccines. The first COVID case in the US occurred in January 2020 (*72*). It was soon discovered that CoV2 caused both symptomatic and asymptomatic infections (the latter being more common in young adults), that asymptomatic individuals could transmit CoV2 (*73, 74*), and that isolation of symptomatic individuals alone would not sufficiently "flatten the curve" of COVID incidence (*37, 75*). By April 2020, most US universities shut down on-campus activities so as to limit CoV2 transmission among their students, staff, and faculty. Many universities established COVID monitoring programs prior to campus reopening as a means of identifying symptomatic and asymptomatic individuals. These monitoring programs varied in their testing modalities (PCR- or antigen-based), cadence (weekly versus biweekly testing) and sample pooling practices (pooled versus individual testing); all monitoring programs, however, had the same goal in mind: enabling safe resumption of on-campus classes and activities. Now that mass COVID testing programs have ended in US, enabling time for processing and reflection, we are sharing the results of our monitoring program which we believe are most relevant to the ongoing issues of community spread, the longevity of mucosal Ig following natural infection, breakthrough infections, and the utility of saliva for assessing Ig responses to newer Omicron subvariants and booster vaccines.

 That the COVID waves in our campus community mirrored those which occurred in surrounding counties, instead of preceding the surrounding county waves, touches on an important question at the time regarding campus reopening: what if any contribution would the influx of students have on COVID incidence in surrounding communities. In January 2021, student returns to university

 campuses were a contentious subject in the US due to the potential risk of contracting the virus and subsequent transmission to surrounding communities. COVID vaccines were not yet widely available to young adults, and—fairly or unfairly—university students were perceived as being more cavalier in their adherence to masking protocols and social distancing. Whether or not the reopening of a given college or university contributed to higher off-campus COVID transmission will depend on several variables (e.g. whether a school was in a state that mandated mask- wearing) (*76*), but in our case the COVID wave that occurred in our university in January 2021 (Wave 1) peaked during the tail end of one which had been ongoing in surrounding counties (compare **FIG 2** to supplemental **FIG S2**). This was also true in Aug 2022, when our campus reopened after summer break and experienced Wave 4, which followed the Delta wave that had already begun in surrounding counties. The timing of Wave 1 and Wave 4 in relation to those in surrounding counties is inconsistent with the argument that our university reopening contributed to COVID incidence in the surrounding communities. Studies at other large universities with COVID policies and monitoring programs similar to our own support this conclusion (*77-79*).

 Early in the COVID pandemic, it was unknown whether natural infection would give rise to Ig responses that were durable and protective, as those against common seasonal coronaviruses are short-lived (only 6 months in some cases) (*80*), or worse still whether the Ig response would actually enhance infection or disease (*81-84*). Regarding the durability and protective capacity of the antibody response to natural CoV2 infection, current knowledge on this subject was recently reviewed (*71*). In our study, at the time of initial PCR positivity we could already detect elevations in CoV2-specific Ig (IgM, IgA, and to a lesser extent IgG) in the saliva of asymptomatic individuals, 552 the degree to which varied by lineage, $CoV2^{Delta}$ being the most immunogenic of the lineages we 553 assessed. Saliva levels of CoV2-specific IgG were substantially higher in Prior^{POS} individuals 554 compared to New^{POS} individuals, were directed against Spike, Spike RBD and (to a lesser extent)

555 the N protein. Potential reasons why Spike-specific IgG (IgG^{Spike}) levels were higher than those 556 of N-specific IgG (IgG^N) include Spike being more antigenic, or alternatively it may reflect an 557 inherent inability of IgG^N to persist in saliva relative to IgG^{Spike}, as is the case in plasma (85). With regards to antibody dependent enhancement (ADE) of virus infection or subsequent disease, this has primarily been studied in the context of flaviviruses (*86*) and is the phenomenon wherein non- neutralizing antibodies amplify viral entry (instead of blocking it). ADE occurs in cell culture and animal infection models of SARS-CoV-1 (*87, 88*) and MERS-CoV (*89*), as well as feline infectious peritonitis coronavirus (FIPV) (*90, 91*). B cells from convalescent COVID patients can produce monoclonal antibodies that enhance the ACE2-binding capacity of Spike and CoV2 infectivity in cell culture (*92, 93*); however, these same monoclonal antibodies did not enhance CoV2 infection in mouse or macaque models (*92*), nor has evidence of vaccine-enhanced disease (VED) been observed in the hamster, ferret or macaque COVID models (*94, 95*). The circumstances and extent to which ADE occurring following CoV2 infection nevertheless remains an active area of research (*96-98*).

 When COVID vaccine doses were in short supply (early 2021), university students were generally not considered a vaccine priority by national public health agencies. By the time COVID vaccines were widely available, non-trivial levels of vaccine hesitancy had arisen among university students in many countries for many reasons (*99*). Vaccine hesitancy was reinforced by the occurrence of 573 breakthrough infections with CoV2^{Delta} (100, 101), the first lineage to emerge after vaccines had become more widely available in Summer 2021. If vaccines were effective, conventional logic at the time being, how then could a vaccinated individual still become PCR^{POS}? Our current understanding is that a combination of three factors affects susceptibility to breakthrough infections: (1) antibody levels at the time of virus exposure, (2) the neutralizing capacity of these antibodies, and (3) the amount of virus to which a vaccinee is exposed. Our data demonstrate 579 that saliva IgG^{Spike} levels were comparable between CoV^{Delta}-infected vaccinees (Vax^{POS}PCR^{POS})

580 and uninfected vaccinees (Vax^{POS}PCR^{NEG}), but that the collective inhibitory capacity of this 581 IgG^{Spike} and other saliva antibodies differed between groups, with Vax^{POS}PCR^{POS} saliva being less 582 inhibitory than Vax^{POS}PCR^{NEG} saliva (FIG 7B). If the saliva Ig response is representative of that which occurs in other parts of the upper airway, then the combination of weak neutralization capacity and higher viral loads, which were typical of the Delta wave (Wave 4 of **FIG 3D**), created 585 conditions that were conducive to $Cov2^{Delta}$ breakthrough infections. Our observation that 586 CoV2^{Delta} was more concentrated in saliva of asymptomatic individuals is consistent with work 587 showing CoV2^{Delta}-infected individuals were more likely to transmit virus before developing symptoms, compared to individuals infected with pre-Delta lineages (*102*).

 The largest COVID wave our university community experienced was caused by the Omicron lineage. The Omicron lineage spread rapidly after its first detection in southern Africa in November 2021 (*11, 103*); the >30 amino acid substitutions in Spike enabled Omicron to bind ACE2 with higher affinity, as well as escape the anti-Spike antibody response elicited by either natural infection or vaccination with pre-Omicron lineages or vaccines (*104-106*). The immunoevasive properties of Omicron are consistent with its causing a COVID wave in our community after vaccine mandates had been established. The rapidity with which Omicron took over was observed in other university settings which, like ours, were highly vaccinated at the time (*107*). Compared to infections caused by the Delta lineage, those by Omicron tend to cause less severe disease (*108*), which may be due in whole or part to its being enriched in upper airways (including the oral cavity) as opposed to the lower airways (*39-43*). Omicron variants BA.1 and BA.2 were the last lineages detected in our university community before our testing program ended in May 2022. Since then CoV2 has continued to evolve, there now being additional Omicron variants (BA.4, BA.5, BA.2.12.1, BA.2.75, XBB) and "Scrabble" subvariants (BQ.1 and BQ1.1) with Spike protein sequences that further desensitize the virus to *in vitro* neutralization by many (but not all) monoclonal therapies (*109-112*), as well as convalescent plasma (*113*). Since Omicron has a higher tropism for the nasopharyngeal and oral cavities than that of pre-Omicron lineages (*39- 43*), saliva antibodies may be more important inhibitors of Omicron transmission than plasma or lower airway antibodies, and saliva—the collection of which is far easier than blood—may be more suitable for rapid determination of whether someone has neutralizing capacity against future CoV2 variants that have yet to emerge.

 The limitations of our study are as follows: (1) Since participants in our monitoring program provided saliva on a weekly basis, we cannot know the exact date on which someone was infected, rather only that they were infected 0-7 days prior to their scheduled test; (2) By only 615 measuring CoV2-specific Ig in individuals whose C_T values fell within a narrow range (thus normalizing for viral load), we cannot make any statements regarding the relationship between 617 lower or higher C_T values and CoV2-specific Ig levels; (3) Although we can correlate saliva 618 samples' Spike inhibition capacity with their corresponding IgM^{Spike}, IgA^{Spike} and IgG^{Spike} levels, we cannot definitively state which of these isotypes most contributed to inhibition; (4) Finally, we did 620 not measure CoV2-specific Ig levels in individuals infected with CoV2^{O-BA.1} or CoV2^{O-BA.2}, a reason being at that stage in the pandemic (i.e. Waves 5-6 in our community) vaccine mandates were in place, and boosters were becoming available, making it difficult if not impossible to discern what 623 Levels of IgM^{Spike}, IgA^{Spike} and IgG^{Spike} were due to vaccination versus boosters versus Omicron infection.

ACKNOWLEDGEMENTS

 We would like to acknowledge the hundreds of Ohio State staff and student employees who collected, transported and processed saliva during the period that our campus testing program was active. We would also like to acknowledge the research compliance expertise of Tish Denlinger (Office of Responsible Research Practices) and Angela Emerson (Office of Research), the technical expertise of Dr. Arpita Agrawal, Brian Gribble, and Trina Wemlinger (Center for Clinical and Translational Science), the general lab assistance of Sam Hagenbaugh and Elizabeth Griffin (TOPS Program), and documentation assistance of Marie Klever (Infectious Disease Institute). This work was supported by the Analytical and Development Laboratory of the Clinical Research Center/Center for Clinical Research Management of Wexner Medical Center, the OSU College of Medicine (Microbial Infection & Immunity Department), OSU College of Public Health (Epidemiology Division), and the OSU Infectious Disease Institute.

REFERENCES

- 1. G. T. Keusch *et al.*, Pandemic origins and a One Health approach to preparedness and prevention: Solutions based on SARS-CoV-2 and other RNA viruses. *Proc Natl Acad Sci U S A* **119**, e2202871119 (2022).
- 2. https://covid19.who.int.
- 3. S. E. Galloway *et al.*, Emergence of SARS-CoV-2 B.1.1.7 Lineage United States, December 29, 2020-January 12, 2021. *MMWR Morb Mortal Wkly Rep* **70**, 95-99 (2021).
- 4. H. Tegally *et al.*, Detection of a SARS-CoV-2 variant of concern in South Africa. *Nature* **592**, 438-443 (2021).
- 5. J. P. Evans, S. L. Liu, Role of host factors in SARS-CoV-2 entry. *J Biol Chem* **297**, 100847 (2021).
- 6. D. Zhou *et al.*, Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera. *Cell* **184**, 2348-2361 e2346 (2021).
- 7. E. Volz *et al.*, Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. *Nature* **593**, 266-269 (2021).
- 8. N. G. Davies *et al.*, Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. *Nature* **593**, 270-274 (2021).
- 9. N. R. Faria *et al.*, Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. *Science* **372**, 815-821 (2021).
- 10. P. Mlcochova *et al.*, SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature* **599**, 114-119 (2021).
- 11. R. Viana *et al.*, Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa. *Nature* **603**, 679-686 (2022).
- 12. J. Scholey *et al.*, Life expectancy changes since COVID-19. *Nat Hum Behav*, (2022).
- 13. J. Q. Xu, S. L. Murphy, K. D. Kochanek, E. Arias, Mortality in the United States, 2021. *NCHS Data Brief, no 456. Hyattsville, MD: National Center for Health Statistics.* , (2022).
- 14. J. Zhao *et al.*, Rapid generation of a mouse model for Middle East respiratory syndrome. *Proc Natl Acad Sci U S A* **111**, 4970-4975 (2014).
- 15. Y. Yao *et al.*, An animal model of MERS produced by infection of rhesus macaques with MERS coronavirus. *J Infect Dis* **209**, 236-242 (2014).
- 16. T. H. Jang *et al.*, The structure of a novel antibody againstthe spike protein inhibits Middle East respiratory syndrome coronavirus infections. *Sci Rep* **12**, 1260 (2022).
- 17. L. Du *et al.*, A conformation-dependent neutralizing monoclonal antibody specifically 670 targeting receptor-binding domain in Middle East respiratory syndrome coronavirus spike protein. *J Virol* **88**, 7045-7053 (2014).
- 18. C. Ma *et al.*, Intranasal vaccination with recombinant receptor-binding domain of MERS- CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines. *Vaccine* **32**, 2100-2108 (2014).
- 19. F. Song *et al.*, Middle East respiratory syndrome coronavirus spike protein delivered by modified vaccinia virus Ankara efficiently induces virus-neutralizing antibodies. *J Virol* **87**, 11950-11954 (2013).

- 21. H. Mou *et al.*, The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. *J Virol* **87**, 9379-9383 (2013).
- 22. D. Sterlin *et al.*, IgA dominates the early neutralizing antibody response to SARS-CoV-2. *Sci Transl Med* **13**, (2021).
- 23. D. Kline *et al.*, Estimating seroprevalence of SARS-CoV-2 in Ohio: A Bayesian multilevel poststratification approach with multiple diagnostic tests. *Proc Natl Acad Sci U S A* **118**, (2021).
- 24. D. F. Robbiani *et al.*, Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* **584**, 437-442 (2020).
- 25. E. M. Bloch *et al.*, Deployment of convalescent plasma for the prevention and treatment of COVID-19. *J Clin Invest* **130**, 2757-2765 (2020).
- 26. L. Estcourt, J. Callum, Convalescent Plasma for Covid-19 Making Sense of the Inconsistencies. *N Engl J Med* **386**, 1753-1754 (2022).
- 27. https://www.fda.gov/news-events/press-announcements/fda-takes-key-action-fight-against-covid-19-issuing-emergency-use-authorization-first-covid-19.
- 28. https://www.fda.gov/news-events/press-announcements/fda-takes-additional-action-fight-against-covid-19-issuing-emergency-use-authorization-second-covid.
- 29. https://www.fda.gov/news-events/press-announcements/fda-issues-emergency-use-authorization-third-covid-19-vaccine.
- 30. D. H. Barouch, Covid-19 Vaccines Immunity, Variants, Boosters. *N Engl J Med* **387**, 1011- 1020 (2022).
- 31. A. G. Johnson *et al.*, COVID-19 Incidence and Death Rates Among Unvaccinated and Fully Vaccinated Adults with and Without Booster Doses During Periods of Delta and Omicron Variant Emergence - 25 U.S. Jurisdictions, April 4-December 25, 2021. *MMWR Morb Mortal Wkly Rep* **71**, 132-138 (2022).
- 32. L. R. Baden *et al.*, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. *N Engl J Med* **384**, 403-416 (2021).
- 33. F. P. Polack *et al.*, Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl J Med* **383**, 2603-2615 (2020).
- 34. D. Bojadzic *et al.*, Small-Molecule Inhibitors of the Coronavirus Spike: ACE2 Protein- Protein Interaction as Blockers of Viral Attachment and Entry for SARS-CoV-2. *ACS Infect Dis* **7**, 1519-1534 (2021).
- 35. Y. Huang, C. Yang, X. F. Xu, W. Xu, S. W. Liu, Structural and functional properties of SARS- CoV-2 spike protein: potential antivirus drug development for COVID-19. *Acta Pharmacol Sin* **41**, 1141-1149 (2020).
- 36. W. S. Hart, P. K. Maini, R. N. Thompson, High infectiousness immediately before COVID- 19 symptom onset highlights the importance of continued contact tracing. *Elife* **10**, (2021).
- 37. M. A. Johansson *et al.*, SARS-CoV-2 Transmission From People Without COVID-19 Symptoms. *JAMA Netw Open* **4**, e2035057 (2021).

- 81. W. S. Lee, A. K. Wheatley, S. J. Kent, B. J. DeKosky, Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies. *Nat Microbiol* **5**, 1185-1191 (2020).
- 82. A. M. Arvin *et al.*, A perspective on potential antibody-dependent enhancement of SARS-CoV-2. *Nature* **584**, 353-363 (2020).
- 83. B. S. Graham, Rapid COVID-19 vaccine development. *Science* **368**, 945-946 (2020).
- 84. A. Iwasaki, Y. Yang, The potential danger of suboptimal antibody responses in COVID-19. *Nat Rev Immunol* **20**, 339-341 (2020).
- 85. J. Van Elslande *et al.*, Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection. *Diagn Microbiol Infect Dis* **103**, 115659 (2022).
- 86. K. A. Dowd, T. C. Pierson, Antibody-mediated neutralization of flaviviruses: a reductionist view. *Virology* **411**, 306-315 (2011).
- 87. S. F. Wang *et al.*, Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins. *Biochem Biophys Res Commun* **451**, 208-214 (2014).
- 88. Y. W. Kam *et al.*, Antibodies against trimeric S glycoprotein protect hamsters against SARS- CoV challenge despite their capacity to mediate FcgammaRII-dependent entry into B cells in vitro. *Vaccine* **25**, 729-740 (2007).
- 89. Y. Wan *et al.*, Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry. *J Virol* **94**, (2020).
- 90. T. Takano, C. Kawakami, S. Yamada, R. Satoh, T. Hohdatsu, Antibody-dependent enhancement occurs upon re-infection with the identical serotype virus in feline infectious peritonitis virus infection. *J Vet Med Sci* **70**, 1315-1321 (2008).
- 91. T. Hohdatsu *et al.*, Antibody-dependent enhancement of feline infectious peritonitis virus infection in feline alveolar macrophages and human monocyte cell line U937 by serum of cats experimentally or naturally infected with feline coronavirus. *J Vet Med Sci* **60**, 49-55 (1998).
- 92. D. Li *et al.*, In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. *Cell* **184**, 4203-4219 e4232 (2021).
- 93. Y. Liu *et al.*, An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. *Cell* **184**, 3452-3466 e3418 (2021).
- 94. K. R. Bewley *et al.*, Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques. *Sci Adv* **7**, eabg7996 (2021).
- 95. C. Li *et al.*, Absence of Vaccine-enhanced Disease With Unexpected Positive Protection 844 Against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by Inactivated Vaccine Given Within 3 Days of Virus Challenge in Syrian Hamster Model. *Clin Infect Dis* **73**, e719-e734 (2021).
- 96. H. S. Ismanto *et al.*, Landscape of infection enhancing antibodies in COVID-19 and healthy donors. *Comput Struct Biotechnol J* **20**, 6033-6040 (2022).
- 97. S. Mu *et al.*, Neutralizing antibodies from the rare convalescent donors elicited antibody- dependent enhancement of SARS-CoV-2 variants infection. *Front Med (Lausanne)* **9**, 952697 (2022).
- 98. C. Gartlan *et al.*, Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses. *Front Immunol* **13**, 882972 (2022).

 99. M. Schafer *et al.*, Determinants of university students' COVID-19 vaccination intentions and behavior. *Sci Rep* **12**, 18067 (2022). 100. T. Dzinamarira *et al.*, Unpacking the Implications of SARS-CoV-2 Breakthrough Infections on COVID-19 Vaccination Programs. *Vaccines (Basel)* **10**, (2022). 101. A. Haque, A. B. Pant, Mitigating Covid-19 in the face of emerging virus variants, breakthrough infections and vaccine hesitancy. *J Autoimmun* **127**, 102792 (2022). 102. M. Kang *et al.*, Transmission dynamics and epidemiological characteristics of SARS-CoV-2 Delta variant infections in Guangdong, China, May to June 2021. *Euro Surveill* **27**, (2022). 103. C. Fischer *et al.*, Gradual emergence followed by exponential spread of the SARS-CoV-2 Omicron variant in Africa. *Science*, eadd8737 (2022). 104. R. Nutalai *et al.*, Potent cross-reactive antibodies following Omicron breakthrough in vaccinees. *Cell* **185**, 2116-2131 e2118 (2022). 105. L. Liu *et al.*, Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2. *Nature* **602**, 676-681 (2022). 106. E. Cameroni *et al.*, Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. *Nature* **602**, 664-670 (2022). 107. B. A. Petros *et al.*, Early introduction and rise of the Omicron SARS-CoV-2 variant in highly vaccinated university populations. *Clin Infect Dis*, (2022). 108. N. van Doremalen *et al.*, SARS-CoV-2 Omicron BA.1 and BA.2 are attenuated in rhesus macaques as compared to Delta. *Sci Adv* **8**, eade1860 (2022). 109. E. Takashita *et al.*, In Vitro Efficacy of Antiviral Agents against Omicron Subvariant BA.4.6. *N Engl J Med* **387**, 2094-2097 (2022). 110. M. Cox *et al.*, SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies. *Nat Rev Microbiol*, 1-13 (2022). 111. Y. J. Park *et al.*, Imprinted antibody responses against SARS-CoV-2 Omicron sublineages. *Science* **378**, 619-627 (2022). 112. M. Hoffmann *et al.*, The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. *Cell* **185**, 447-456 e411 (2022). 113. P. Qu *et al.*, Evasion of neutralizing antibody responses by the SARS-CoV-2 BA.2.75 variant. *Cell Host Microbe* **30**, 1518-1526 e1514 (2022).

887 **FIGURE LEGENDS**

888

889 **FIGURE 1. Overview of our university COVID monitoring program and workflow.** (**A**) Map 890 of Ohio with locations of the six university campuses which participated in the COVID monitoring 891 program. (**B**) On and prior to the day of testing, each individual assessed themselves for one or 892 more COVID symptoms (see *Methods* for complete list). If symptomatic, the individual was given 893 a clinical referral and instructed to not go to their on-campus testing facility, to prevent contagion. 894 If asymptomatic, the individual provided a saliva sample which was tested (typically within 24 895 hours of sample provision) via qRT-PCR for the presence of the CoV2 N gene. Individuals were 896 notified as soon as possible as to whether their sample was negative (PCR^{NEG}) or positive 897 (PCR^{POS}) for the virus, a positive result being a $C_T \leq 40$. PCR^{POS} samples were subsequently 898 aliquoted and used for both CoV2 lineage identification and measuring the concentrations of 899 immunoglobulin against specific CoV2 antigens (CoV2-Ig). The vast majority of PCR^{NEG} samples 900 were discarded; however, a minority were retained and used for CoV2-Ig measurements. PCR^{POS} 901 and PCR^{NEG} samples were otherwise treated identically.

902

 FIGURE 2. The incidence of PCR positivity among asymptomatic members of our university community. Saliva samples from asymptomatic individuals were collected on a daily basis and tested by qRT-PCR for the presence of the CoV2 N gene. Shown are the number of 906 PCR^{POS} saliva samples identified each day during the period spanning Jan 2021 \rightarrow May 2022, with each bar representing a single day. Above the graph is a timeline depicting when COVID vaccine availability shifted in Ohio (i.e. when the national vaccination priority expanded from vulnerable populations to encompass anyone >15 years of age), as well as indications of the deadlines by which all university community members were required to have received their first and second vaccine dose of either the BNT162b2 or mRNA-1273 vaccines. Below the graph are

912 indications of the periods we refer to as Waves 1-6, a wave being defined as when the daily 913 PCR^{POS} case count exceeded the period median (15) for \geq 3 weeks, as well Blue shading indicates 914 when the samples we used for CoV2 Ig measurements were collected.

915

916 **FIGURE 3. Saliva CoV2 viral loads among asymptomatic members of our university** 917 **community.** (A) Box plot representation of all the C_T values of all the PCR^{POS} saliva samples 918 during each week of the period spanning Jan 2021 \rightarrow Jun 2022. The blue line passes through 919 the median C_T value of each week. Below the graph are indications of the periods corresponding 920 to Waves 1-6 of the prior figure. (**B**) Scatter plot representation of the same C_T value data as in 921 (**A**) above, the exceptions being daily data are shown (as opposed to weekly composites) and 922 samples with a $C_T > 33$ are omitted (these could not be sequenced due to insufficient amounts of 923 genetic material). Each dot represents an individual sample; the color of each diamond indicates 924 the CoV2 lineage present (Green, CoV2^{US}; Pink, CoV2^{Alpha}; White, CoV2^{Beta}; Blue, CoV2^{Gamma}; 925 Red, CoV2^{Delta}; Gold, CoV2^{O-BA.1}; Orange, CoV2^{O-BA.2}). Gray diamonds indicate samples whose 926 lineage was not a VOC. Black squares indicate a sequence that did not align to known lineages 927 and thus could not be assigned. Note that $CoV2^{Beta}$ only appeared once in our university 928 community, on Apr 15 2021. (C) The C_T value and (D) calculated CoV2 genome copy 929 concentration in of each positive sample during Wave 1, Wave 2, Wave 3, Wave 4, Wave 5 and 930 Wave 6. The "Vax" arrow indicates when community vaccine requirements went into effect (after 931 Wave 4, before Wave 5). Asterisks indicate those inter-wave differences that were statistically 932 significant, as determined by one way ANOVA (* $p \le 0.05$, ** $p \le 0.005$, *** $p \le 0.0005$, *** $p \le$ 933 0.00005).

934

935 **FIGURE 4. Spike-specific Ig levels in the saliva of newly positive, asymptomatic individuals** 936 **at the time of PCR testing.** Saliva samples from individuals who were newly positive (New^{POS},

937 PCR positive for the first time ever) for either the CoV2^{US}, CoV2^{Alpha}, CoV2^{Gamma} or CoV2^{Delta} 938 lineage were used to measure the concentrations of (A) $\log M^{\text{Spike}}$, (B) $\log A^{\text{Spike}}$ and (C) $\log G^{\text{Spike}}$. The 939 $CoV2^{Anc}$ Spike was used as the capture antigen in each case, and concentrations are expressed 940 as World Health Organization (WHO) binding antibody units (BAU) per mL. PCR^{NEG} saliva 941 collected in early 2020, from healthy individuals living in the US with no COVID history, was tested 942 in the same manner used to estimate "pre-pandemic" levels of I gM^{Spike}, IgA^{Spike} and IgG^{Spike} 943 binding, which are represented by the dashed lines on each graph. X , values that were considered 944 outliers but are nevertheless shown for completeness and are included in all statistical group 945 comparisons. $*$ p \leq 0.05, as determined by unpaired Wilcoxon tests with Benjamini-Hochberg 946 adjustment.

947

948 **FIGURE 5. Nucleocapsid- and Spike-specific IgG levels in saliva of newly positive,** 949 **asymptomatic individuals versus prior positive, asymptomatic individuals.** Saliva from 950 New^{POS} individuals infected with either CoV2^{US} or CoV2^{Alpha}, as well as PCR^{NEG} saliva from 951 individuals who had been infected 3-9 months prior (Prior^{POS}) with either CoV2^{US}, CoV2^{Alpha} or a 952 non-VOC, were used to measure the concentrations of (**A**) Nucleocapsid-specific IgG, (**B**) Spike-953 specific IgG, and (C) Spike RBD-specific IgG. $*$ p \leq 0.05, as determined by unpaired Wilcoxon test 954 with Benjamini-Hochberg adjustment.

955

956 **FIGURE 6. Spike-specific Ig levels in saliva of CoV2^{Delta}-infected unvaccinated individuals,** 957 **CoV2^{Delta}-infected vaccinees, and uninfected vaccinees. During and shortly after COVID** 958 Wave 4 (i.e. that which was caused by CoV2^{Delta}), saliva from three groups of individuals were 959 collected and used for Ig measurements: those who had not been fully vaccinated and were 960 positive for the CoV2^{Delta} lineage (Vax^{NEG}PCR^{POS}), those who had been fully vaccinated and were 961 positive for the CoV2^{Delta} lineage (Vax^{POS}PCR^{POS}), and those who had been fully vaccinated and

962 were negative for any CoV2 lineage (Vax^{POS}PCR^{NEG}). Shown are the (A) IgM^{Spike}, (B) IgA^{Spike} and 963 (C) IgG^{Spike} levels in each individual sample per group. ^X, values that were considered outliers but 964 are nevertheless shown for completeness and are included in all statistical group comparisons. * $965 \text{ p}\leq 0.05$, as determined by unpaired Wilcoxon tests with Benjamini-Hochberg adjustment.

966

967 FIGURE 7. Inhibition of Spike function by saliva of CoV2^{Delta}-infected unvaccinated 968 **individuals, CoV2^{Delta}-infected vaccinees, and uninfected vaccinees (A) Depiction of the** 969 probe-conjugated ACE2 displacement assay used to measure saliva samples' ability to inhibit 970 CoV2 Spike binding to its human receptor, ACE2. The samples in this case were from 971 VAX^{NEG}PCR^{POS}, VAX^{POS}PCR^{POS} and VAX^{POS}PCR^{NEG} individuals (the same samples used for 972 IgM^{Spike}, IgA^{Spike} and IgG^{Spike} measurements in **FIG 6** above). (**B**) The percent inhibition value of 973 each individual sample in each group. Within the (C-E) VAX^{NEG}PCR^{POS} group, (F-H) 974 VAX^{POS}PCR^{POS} group, and (I-K) VAX^{POS}PCR^{NEG} group, the relationship between an individual 975 samples' inhibition value and cognate (C,F,H) IgM^{Spike} concentration, (D,G,I) IgM^{Spike} 976 concentration, and (**E,H,J**) IgG^{Spike} concentration. Graph insets indicates the Multiple R-squared 977 value associated with the linear regression model of the respective data set (i.e. the % variation 978 in inhibition that can be explained by the indicated Ig concentration), as well as its p-value (i.e. 979 the significance of the linear model as a whole).

980

981 **Supplemental FIGURE S1. The CoV2 antigens and components relevant to our study.** (**A**) 982 Depiction of CoV2 and its RNA genome, nucleocapsid (N, yellow) and Spike proteins, the latter 983 being differentially colored to indicate the Receptor Binding Domain (RBD, blue) and non-RBD 984 regions (green). (**B**) The amino acids which distinguish the CoV2^{Anc} Spike protein from CoV2^{US} 985 (also known as B.1.2), CoV2^{Alpha}, CoV2^{Gamma} and CoV2^{Delta}, as well as the Omicron lineages 986 CoV2^{O-BA.1}, CoV2^{O-BA.2}, CoV2^{O-BA.4} and CoV2^{O-BA.5}.

987

Supplemental FIGURE S2. The waves of COVID incidence in the counties surrounding our

 university campuses. Daily COVID cases in the counties surrounding each campus of our university, as reported by the Ohio Department of Health (ODH), for the period spanning Jan 2021 \rightarrow May 2022. Shown are the data for (A) Franklin County, which surrounds the OSU-Columbus campus; (**B**) Licking County, which surrounds the OSU-Newark campus; (**C**) Richland County, which surrounds the OSU-Mansfield campus; (**D**) Allen County, which surrounds the OSU-Lima campus; (**E**) Marion County, which surrounds the OSU-Marion campus; and (**F**) Wayne County, which surrounds the OSU-Wooster campus. Overlaid onto each graph are the dates which correspond to the six COVID waves (W1-W6) that occurred in our campus community (see **FIG 2**).

Supplemental FIGURE S3. **The age of individuals whose PCRPOS saliva sample was viral** 1000 genome sequenced. The age range of individuals whose saliva was PCR^{POS} and sequenced throughout the monitoring period. Violin plots depicting the ages of individuals whose saliva was 1002 PCR^{POS} and sequenced each month.

 Supplemental FIGURE S4. The representation of each sex among individuals whose PCR^{POS} saliva met sequencing criteria. The percent of males, females and undefined sex 1006 among individuals whose saliva was PCR^{POS} and sequenced for lineage identification for each 1007 week of our study period, the criteria for sequencing being a $C_T \leq 33$. Overlaid onto the graph in gray are the periods corresponding to Waves 1-6 in our university community. The average values for each sex across the entire study period are indicated by the hatched lines.

Supplemental FIGURE S5. VOC Spike-specific Ig levels in the saliva of newly positive,

asymptomatic individuals at the time of PCR testing. Saliva samples that were positive for

1013 either the CoV2^{US}, CoV2^{Alpha}, CoV2^{Gamma} or CoV2^{Delta} lineage were used to measure the 1014 concentrations of (A) IgM^{Spike}, (B) IgA^{Spike} and (C) IgG^{Spike}. Varying by column were the coating 1015 antigens (Ag) used for each measurement, the Ag being recombinant forms of either the CoV^{Anc} 1016 Spike (Column 1), CoV2^{Alpha} Spike (Column 2), CoV2^{Beta} Spike (Column 3), and CoV2^{Gamma} Spike 1017 (Column 4). Antibody levels are expressed in arbitrary units of luminescence. Note that the CoV^{Anc} 1018 -specific IgM, IgA and IgG values in (**A-C**) Column 1 were transformed into WHO Binding Antibody 1019 Units (BAUs) for **FIG 4.**

1020

Supplemental FIGURE S6. VOC Spike-specific Ig levels in saliva of CoV2Delta 1021 **-infected unvaccinated individuals, CoV2Delta** 1022 **-infected vaccinees, and uninfected vaccinees.** During 1023 and after COVID Wave 4 (i.e. that which was caused by CoV2^{Delta}), saliva from three groups of 1024 individuals were collected and used for Ig measurements: those who had not been fully 1025 vaccinated and were positive for CoV2^{Delta} (Vax^{NEG} PCR^{POS}), those who had been fully vaccinated 1026 and were positive for the CoV2^{Delta} (Vax^{POS} PCR^{POS}), and those who had been fully vaccinated 1027 and were negative for any CoV2 lineage (Vax^{POS} PCR^{NEG}). Shown for each individual in each 1028 group are the levels of (A) $\log M^{\text{Spike}}$, (B) $\log A^{\text{Spike}}$ and (C) $\log G^{\text{Spike}}$ which bind to four different coating 1029 antigens (Ag), the Ag being recombinant forms of either the CoV^{Anc} Spike (Column 1), CoV2^{Alpha} 1030 Spike (Column 2), CoV2^{Beta} Spike (Column 3), CoV2^{Gamma} Spike (Column 4) and CoV2^{Delta} Spike 1031 (Column 5). Antibody levels are expressed in arbitrary units of luminescence. Note that the CoV^{Anc} 1032 -specific IgM, IgA and IgG values in (**A-C**) Column 1 were transformed into WHO Binding Antibody 1033 Units (BAUs) for **FIG 6.**

FIGURE 1

FIGURE 2

FIGURE 3

NewPOS individuals

FIGURE 5

A

All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.01.30.23285195;](https://doi.org/10.1101/2023.01.30.23285195) this version posted February 1, 2023. The copyright holder for this preprint

FIGURE 7

Substitution (relative to Ancestral)

Deletion (relative to Ancestral)

C Insertion of EPE at postion 214 (Omicron BA.1 specific)

Supplemental FIGURE S1

Supplemental FIGURE S2

Supplemental FIGURE S3

Supplemental FIGURE S4

mediRxiv preprint dontingtes://doi.orgctetng 0g/2023.01999!28295195; this version posted February 1, 2023. The copyright holder for this preprint

CoV2 lineage present in saliva

CoV2 lineage present in saliva

Supplemental FIGURE S5

CoV2Anc Spike CoV2Alpha Spike CoV2Beta Spike CoV2Gamma Spike CoV2Delta Spike Guide Allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.01.30.23285195;](https://doi.org/10.1101/2023.01.30.23285195) this version posted February 1, 2023. The copyright holder for this preprint

C

A

Coating CoV2Anc Spike CoV2Alpha Spike CoV2Beta Spike CoV2Gamma Spike CoV2Delta Spike antigen: 700

Supplemental FIGURE S6